---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-083019"
form_type: "8-K"
ticker: "HOOK"
cik: "0001760542"
company_name: "HOOKIPA Pharma Inc."
filed_at: "2024-07-26T23:59:59+00:00"
generated_at: "2026-05-31T15:58:57.531770+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# HOOKIPA Pharma appoints Dr. Malte Peters CEO and Terry Coelho CFO; launches strategic review for HB-200

## Summary
- Dr. Malte Peters appointed CEO & President effective July 22, 2024; salary $630k, RSU award $700k.
- Terry Coelho appointed EVP & CFO effective July 22, 2024; salary $480k, signing bonus $240k, RSU $450k.
- Former CEO Jörn Aldag and CFO Reinhard Kandera separated July 22, resigned from board July 23.
- Sean Cassidy appointed independent director and Audit Committee chair effective July 22.
- Company launches strategic review to focus on HB-200 and create shareholder value; no impact on operations or trials.

## SEC filing metadata
- accession: 0001104659-24-083019
- form_type: 8-K
- ticker: HOOK
- cik: 0001760542
- company_name: HOOKIPA Pharma Inc.
- filed_at: 2024-07-26T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 5.02, 7.01, 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1760542/000110465924083019/0001104659-24-083019-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1760542/000110465924083019/tm2420181d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-083019
- JSON: https://secwatch.observer/filing/0001104659-24-083019.json
- Plain text: https://secwatch.observer/filing/0001104659-24-083019.txt

## Key facts
- Executive change
  Malte Peters was appointed as Chief Executive Officer and President at HOOKIPA Pharma Inc..
  - Action: appointed
  - Role: Chief Executive Officer and President
  source text: the Company’s board of directors (the “Board”) appointed Malte Peters, M.D., as the Company’s Chief Executive Officer and President, effective July 22, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1760542/000110465924083019/0001104659-24-083019-index.htm
- Executive change
  Reinhard Kandera departed as Chief Financial Officer at HOOKIPA Pharma Inc..
  - Action: separated
  - Role: Chief Financial Officer
  source text: On July 22, 2024, Reinhard Kandera separated as the Chief Financial Officer of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1760542/000110465924083019/0001104659-24-083019-index.htm
- Executive change
  Reinhard Kandera resigned as Director at HOOKIPA Pharma Inc..
  - Action: resigned
  - Role: Director
  source text: Mr. Kandera also resigned from his position as a director of the Company on July 23, 2024 following his separation as Chief Financial Officer
  evidence_url: https://www.sec.gov/Archives/edgar/data/1760542/000110465924083019/0001104659-24-083019-index.htm
- Executive change
  Joern Aldag departed as Chief Executive Officer at HOOKIPA Pharma Inc..
  - Action: separated
  - Role: Chief Executive Officer
  source text: On July 22, 2024, Joern Aldag separated as the Chief Executive Officer of HOOKIPA Pharma Inc. (the “Company”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1760542/000110465924083019/0001104659-24-083019-index.htm
- Executive change
  Joern Aldag resigned as Director at HOOKIPA Pharma Inc..
  - Action: resigned
  - Role: Director
  source text: Mr. Aldag also resigned from his position as a director of the Company on July 23, 2024 following his separation as Chief Executive Officer
  evidence_url: https://www.sec.gov/Archives/edgar/data/1760542/000110465924083019/0001104659-24-083019-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.